StabiLux Biosciences key facts
- Developer of high-brightness fluorophores designed to improve the reagents that run through flow cytometers.
- It has raised $1.9M across 1 recorded rounds; the latest was Seed Round ($554K) in Apr 2024.
- Notable investors include US National Science Foundation, Invest Detroit Ventures, Lateral Capital Management, Michigan Economic Development, Alligator Holdings — 12 tracked in total.
- StabiLux Biosciences has filed 1 Form D with the SEC, most recently May 2024 ($554K sold to 9 investors).
- Status: Privately Held (backing).
Who backs StabiLux Biosciences
12+- ·The complete investor list: 12 names
- ·Watch StabiLux Biosciences: the Monday email on marks, rounds and moves
StabiLux Biosciences funding rounds
1 roundsHow much has StabiLux Biosciences raised?
StabiLux Biosciences has raised $1.9 million in total; 1 of its rounds is on record. The largest on record was a $554,381 seed round in Apr 2024.
StabiLux Biosciences has filed 1 Form D with the SEC, most recently in May 2024 ($554,381 sold to 9 investors).
StabiLux Biosciences investors
12 investors are on record for StabiLux Biosciences, including US National Science Foundation, Invest Detroit Ventures, Lateral Capital Management and Michigan Economic Development. The seed round in Apr 2024 drew 9 investors.
About StabiLux Biosciences
Developer of high-brightness fluorophores designed to improve the reagents that run through flow cytometers. The company's fluorophores are compatible with current flow cytometers and increase the brightness of fluorophores across the visible range with minimal or no noise distortion, enabling users to detect targeted or cancer cells feasibly.
- Sector
- Healthcare
- HQ
- Ann Arbor, MI, United States
- Founded
- 2014
- Employees
- 9
- Website
- stabilux-biosciences.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
StabiLux Biosciences doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.